Quince Therapeutics Leadership Change
Quince Therapeutics (renaming to IRulya Therapeutics) announced the resignation of CEO Dirk Thye and COO Brendan Hannah, effective October 8, 2026. Brigette Roberts, M.D., has been appointed as the new Chief Executive Officer, bringing a base salary of $600,000 and a 50% target bonus. The leadership transition coincides with a corporate rebrand and a strategic focus on the clinical development of LAM-001 for pulmonary diseases.